Gapping up
In reaction to strong earnings/guidance: AVNW +6.4%, NAV +3.9%, TEU +3.7%, ODP +1.1%, TOL +0.8%, .
M&A news: BTH +19.9% (ViSalus founders agree in principle to acquire majority of ViSalus; Blyth will retain 10% stake ), CNQR +10.9% (attributed to speculation of potential sale), ALTV +6.5% (unanimously rejects unsolicited proposal from Juniper for $8/per, adopts Shareholder Rights Plan), FL +1.2% (DailyMail discusses FL private equity buyout rumors at $70/share), VOD +1.0% (cont M&A spec), RCL +0.8% (to sell Celebrity Century to Ctrip (CTRP)).
Select financial related names showing strength: DB +2.9%, ING +1.9%, HSBC +1.4%.
Other news: CBLI +47.5% (announces green light to proceed with a pre-Emergency Use Authorization submission for entolimod), INFI +40.6% (enters into master clinical supply agreement and material transfer agreement with Roche (RHHBY), co and ABBV announce global collaborization for Duvelisib), PTN +36.3% (licenses Bremelanotide in Europe and other selected countries to Richter),ISNS +18.1% (continued move following +46% gain yest), TTPH +10.7% (announced positive oral dosing data from lead-in of IGNITE 2 Phase 3 trial of eravacycline for the treatment of complicated urinary tract infections), LOCM +8.3% (reaches favorable settlement in patent infringement litigation), VII +7.5% (continued move following +31% gain yest), FLEX +6.3% (Flextronics received shareholder approval to purchase up to 20% of its outstanding shares), RSX +4.2% (media reports of caese fire talks betw Rus/Ukraine), CHL +3.9% (Apple iPhone 6 pre-orders begin at China Mobile (CHL) website, according to reports), EXEL +3.2% (bouncing following yesterday's steep decline), YNDX +3.2% (Russian related name), VSI +2.9% (positive comments on Mad Money), QIWI+2.8% (Russian related name), PSDV +2.7% (reports ILUVIEN for chronic diabetic macular edema receives marketing authorization in Sweden), X +2.6% (looks to be a reaction to Russia/Ukraine headlines; also positive analyst comments), LOCO +2.5% (continues to be highly volatile pre-mkt name), MT +2.4% (trading higher in sympathy with peer X), GPRO +2.3% (positive comments on Mad Money), ACHN +2% (RA Capital Management discloses 18.1% passive stake in 13G filing), VOD +1.3% (M&A spec), BP +1.3% (wants oil spill admin claims removed, according to reports), TSLA +1.3% (positive comments on Mad Money), GNC +1.2% (positive comments on Mad Money), BIDU +1.1% (IndoorAtlas receives $10 mln investment from Baidu and signs exclusive agreement for Chinese Market), NVS +1% (reports Gilenya data to show Novartis is redefining MS treatment goals for patients), AZN +1% (TEVA announces UK High Court gives positive judgment in the Company's patent case against AstraZeneca (AZN)).
Analyst comments: SALT +2.3% (initiated with a Buy at Jefferies), LL +2.3% (upgraded to Outperform from Neutral at Wedbush), BDBD +2.1% (upgraded to Buy from Neutral at Longbow), CRH +2.1% (upgraded to Neutral from Underweight at HSBC Securities), ABB +2.1% (upgraded to Buy from Neutral at BofA/Merrill), DGX +0.9% (added to Conviction Buy list at Goldman)
In reaction to strong earnings/guidance: AVNW +6.4%, NAV +3.9%, TEU +3.7%, ODP +1.1%, TOL +0.8%, .
M&A news: BTH +19.9% (ViSalus founders agree in principle to acquire majority of ViSalus; Blyth will retain 10% stake ), CNQR +10.9% (attributed to speculation of potential sale), ALTV +6.5% (unanimously rejects unsolicited proposal from Juniper for $8/per, adopts Shareholder Rights Plan), FL +1.2% (DailyMail discusses FL private equity buyout rumors at $70/share), VOD +1.0% (cont M&A spec), RCL +0.8% (to sell Celebrity Century to Ctrip (CTRP)).
Select financial related names showing strength: DB +2.9%, ING +1.9%, HSBC +1.4%.
Other news: CBLI +47.5% (announces green light to proceed with a pre-Emergency Use Authorization submission for entolimod), INFI +40.6% (enters into master clinical supply agreement and material transfer agreement with Roche (RHHBY), co and ABBV announce global collaborization for Duvelisib), PTN +36.3% (licenses Bremelanotide in Europe and other selected countries to Richter),ISNS +18.1% (continued move following +46% gain yest), TTPH +10.7% (announced positive oral dosing data from lead-in of IGNITE 2 Phase 3 trial of eravacycline for the treatment of complicated urinary tract infections), LOCM +8.3% (reaches favorable settlement in patent infringement litigation), VII +7.5% (continued move following +31% gain yest), FLEX +6.3% (Flextronics received shareholder approval to purchase up to 20% of its outstanding shares), RSX +4.2% (media reports of caese fire talks betw Rus/Ukraine), CHL +3.9% (Apple iPhone 6 pre-orders begin at China Mobile (CHL) website, according to reports), EXEL +3.2% (bouncing following yesterday's steep decline), YNDX +3.2% (Russian related name), VSI +2.9% (positive comments on Mad Money), QIWI+2.8% (Russian related name), PSDV +2.7% (reports ILUVIEN for chronic diabetic macular edema receives marketing authorization in Sweden), X +2.6% (looks to be a reaction to Russia/Ukraine headlines; also positive analyst comments), LOCO +2.5% (continues to be highly volatile pre-mkt name), MT +2.4% (trading higher in sympathy with peer X), GPRO +2.3% (positive comments on Mad Money), ACHN +2% (RA Capital Management discloses 18.1% passive stake in 13G filing), VOD +1.3% (M&A spec), BP +1.3% (wants oil spill admin claims removed, according to reports), TSLA +1.3% (positive comments on Mad Money), GNC +1.2% (positive comments on Mad Money), BIDU +1.1% (IndoorAtlas receives $10 mln investment from Baidu and signs exclusive agreement for Chinese Market), NVS +1% (reports Gilenya data to show Novartis is redefining MS treatment goals for patients), AZN +1% (TEVA announces UK High Court gives positive judgment in the Company's patent case against AstraZeneca (AZN)).
Analyst comments: SALT +2.3% (initiated with a Buy at Jefferies), LL +2.3% (upgraded to Outperform from Neutral at Wedbush), BDBD +2.1% (upgraded to Buy from Neutral at Longbow), CRH +2.1% (upgraded to Neutral from Underweight at HSBC Securities), ABB +2.1% (upgraded to Buy from Neutral at BofA/Merrill), DGX +0.9% (added to Conviction Buy list at Goldman)